Singapore HSA Publishes GN-15 Revision 15: Reliance Route Still Requires Reference Agency-Approved Indication to Match Singapore Labelling Exactly

On 1 October 2026, the Health Sciences Authority (HSA) of Singapore moved its medical device product registration guidance to Revision 15. GN-15 Guidance on Medical Device Product Registration, Revision 15, runs to 51 pages. Changes are flagged with the marker ">", and they concentrate in two places: a new "Premarket Submission Checklist" line in the Class B and Class C/D submission requirement tables, and a restriction on which bodies may issue ISO 13485 certificates. The guidance also restates the hard conditions of the reliance route: the labelled use approved by the reference regulator must be exactly the same as the use intended for marketing in Singapore, and an application will be placed on stop-clock while the device is subject to a field safety corrective action.

Sources: Health Sciences Authority (Singapore) — GN-15 Guidance on Medical Device Product Registration, Revision 15: https://file.go.gov.sg/gn-15-r15-30-09-2026.pdf (1 October 2026); Health Sciences Authority (Singapore) — Medical devices guidance documents: https://www.hsa.gov.sg/medical-devices/guidance-documents (30 September 2026).

Third revision in seven months

On 1 October 2026, HSA's medical device product registration guidance GN-15 entered Revision 15. The document's version table lists the three most recent editions: R13 dated 10 March 2026, R14 dated 14 September 2026, and R15 dated 1 October 2026. The 51-page guidance has therefore been revised three times in seven months.

A note beneath the version table states that changes in each revision are marked with the symbol ">", and that deleted content may not be displayed. This explains why a straight read-through of R15 may give the impression that little has changed — identifying the changes requires counting the arrows.

The two changes in R15

1. Premarket Submission Checklist added to the submission requirement tables

The first change appears in the submission requirement summary tables in Annex 6 (Class B) and Annex 8 (Class C and D). The first row of both tables now includes a "Premarket Submission Checklist" entry, marked with the R15 arrow.

2. Eligibility of ISO 13485 certificate issuers restricted

The second change concerns the eligibility of the body issuing the ISO 13485 certificate. Table note 7 in Annex 6 and table note 6 in Annex 8 now state that the ISO 13485 certification body must either be accredited by an accreditation body recognised under Global ACI, or itself be a notified body under the EU MDR/IVDR.

Neither change is a major overhaul, but both operate at the level of whether a dossier is accepted in the first place. The former turns a pre-submission self-check list into a formal line item in the tables; the latter locks the issuer of the quality management system certificate to two categories of source. A certificate issued by a body outside those two categories can no longer serve directly as conformity evidence.

Hard condition of the reliance route: the intended use must be identical

Under R15, the review routes for Class B, Class C and Class D devices remain four: full review, abridged review, expedited registration (IBR for Class B, ECR for Class C, EDR for Class D), and priority review within the full review route. Eligibility for the latter routes rests on a single formulation — labelled use identical to that intended for marketing in Singapore — meaning the labelled use approved by the reference agency must be exactly the same as the use intended for marketing in Singapore.

The first condition for Class B immediate registration (IBR) is set out in the greatest detail: at least one HSA independent reference regulatory agency must have approved the same labelled use; the device must have been marketed in that jurisdiction for at least three years; there must have been no death reports and no reports of serious deterioration in health status worldwide in the past three years; there must be no open field safety corrective action at the time of submission; and the device must not have been rejected or withdrawn by any reference agency or by HSA on quality, performance or effectiveness grounds or on safety grounds, including a rejection of a particular model within the same application.

ECR-1 for Class C and EDR-1 for Class D follow the same formulation. The alternative conditions ECR-2 and EDR-2 require that two independent reference agencies have both approved the same use.

HSA's list of independent reference agencies appears in a footnote: Health Canada, Japan's Ministry of Health, Labour and Welfare (MHLW), the US FDA, and TGA together with EU notified bodies.

Two preconditions that are easily missed

Classification mismatch

A note on page 23 of the guidance states that Class B, C and D devices that are classified as Class I or as Class II exempt by the above reference agencies cannot use those approvals to access the abridged, expedited or immediate routes. A product cleared by the FDA through the 510(k) pathway as a Class II device, but classified as Class C in Singapore, cannot rely on that 510(k) to qualify for ECR.

A field safety corrective action freezes the clock

Section 9 addresses review timelines: the target TAT runs from receipt of the application and excludes stop-clock time arising from requests for additional information. If the device is subject to a field safety corrective action (FSCA), the application will be placed on stop-clock until the FSCA is closed or the measures HSA considers necessary have been completed.

Situations in which the reliance route is not available

In the regulatory reliance arrangements in Section 6, borderline products that the Malaysian Medical Device Authority (MDA) and HSA classify differently are excluded. Section 7 on the priority review scheme contains a further exclusion: devices containing registrable therapeutic or medicinal components are not eligible.

These two provisions are not new in R15, but they sit alongside the reliance routes in the same document. Applicants often focus only on the route table near the front and discover at the point of submission that their device falls within an exclusion.

Sources and scope of verification

Sources: Health Sciences Authority (Singapore), GN-15 Guidance on Medical Device Product Registration, Revision 15 (effective 1 October 2026), available at https://file.go.gov.sg/gn-15-r15-30-09-2026.pdf; HSA medical devices guidance documents page at https://www.hsa.gov.sg/medical-devices/guidance-documents. Version dates, page counts, page numbers and clause wording cited in this article are taken from the text of that PDF.

Scope of verification and access date: on 31 October 2026 the full 51-page PDF was reviewed, including the version table (page 4), the Class B review routes and IBR conditions (pages 13 to 17), the Class C and Class D review routes (pages 21 to 26), the review timelines and stop-clock provisions (page 34), and the submission requirement summary tables (Annex 6 and Annex 8). The body of the HSA guidance page could not be retrieved during this review round.

Scope note: this article is an interpretation of a public regulatory document. It does not constitute a conclusion or commitment in respect of any specific product, company or registration application, and does not represent the position of HSA. The R15 changes are as marked with ">" in the source text; because the source notes that deleted content may not be displayed, this article does not exclude the possibility of unmarked adjustments. The content of the document may be updated in subsequent revisions, and actual submissions should be based on the latest version published on the HSA website and on official responses from HSA.

AIMEILI regulatory interpretation

The R15 changes are best understood as a tightening of documentary acceptance criteria rather than a change in the substantive review standard. The addition of the Premarket Submission Checklist to the Class B and Class C/D tables does not create a new evidence requirement, but it converts a previously informal completeness check into a formal, table-level item. In practice, HSA reviewers can now point directly to a defined checklist when a dossier is incomplete, which makes screening outcomes more predictable and less open to negotiation. Applicants should therefore treat the checklist as a mandatory gate before submission and map every line item to a specific dossier section, including gap statements where a requirement does not apply.

The ISO 13485 restriction is the more consequential of the two changes. By limiting acceptable certificate issuers to accreditation bodies recognised under Global ACI or to EU MDR/IVDR notified bodies, HSA has aligned its acceptance of quality management system evidence with the mainstream international accreditation infrastructure. Certificates from certification bodies without those recognitions will no longer be accepted at face value as conformity evidence, which is a supplier-selection issue rather than a documentation-formatting issue: a manufacturer holding a legitimate but non-recognised ISO 13485 certificate may need a fresh certification cycle or a supplementary assessment.

On the reliance route, R15 reaffirms rather than relaxes the position. The phrase "labelled use identical to that intended for marketing in Singapore" is applied strictly, and HSA shows no inclination to accept "substantially equivalent" or "partially overlapping" indications. The IBR conditions are cumulative — approval of the same use, three years of marketing, a clean three-year global safety record, no open FSCA, and no prior rejection or withdrawal on quality, performance, effectiveness or safety grounds. A single unmet element, including the rejection of one model within a previous application, is sufficient to disqualify the application.

The classification-mismatch note and the FSCA stop-clock provision represent two further risk points. The first is a structural issue: reliance eligibility depends on HSA's own classification of the device, not on the foreign classification, so a Class II FDA clearance does not by itself support ECR or IBR. The second is a timing issue: an open FSCA anywhere in the world can suspend the review clock, so safety-event management and registration planning cannot be run as separate workstreams.

Business impact

For global manufacturers, distributors, CROs and regulatory affairs teams, the practical consequences of R15 fall into four areas.

• Submission readiness. The Premarket Submission Checklist is now a formal table item for Class B and Class C/D submissions. Dossiers assembled without a line-by-line checklist cross-reference are more likely to be returned at screening, which adds a full review cycle to launch timelines.
• Quality management system certification. Manufacturers whose ISO 13485 certificates are issued by bodies without Global ACI-recognised accreditation or EU MDR/IVDR notified body status should review their certification portfolio immediately. Remediation can take a full audit cycle, so this should be treated as a lead-time risk for Singapore registration plans, not a desk-level correction.
• Reliance strategy. Products whose Singapore intended use differs from the reference agency's approved indication cannot use abridged, expedited or immediate routes and must plan for full review. The same applies to devices whose reference jurisdiction classification is Class I or Class II exempt, and to devices containing registrable therapeutic or medicinal components, which are excluded from the priority review scheme.
• Post-market and safety oversight. The requirement for a clean three-year global safety record and the stop-clock triggered by an FSCA mean that vigilance data, corrective action status and registration timing must be coordinated. A single open corrective action can delay an otherwise complete application until it is closed.

Given the pace of revision — three editions in seven months — teams should build a routine review of GN-15 into their Singapore regulatory intelligence cycle and verify requirements against the latest version on the HSA website before each submission, rather than relying on earlier interpretations.

Information sources

• Health Sciences Authority (Singapore) — GN-15 Guidance on Medical Device Product Registration, Revision 15 — 1 October 2026
• Health Sciences Authority (Singapore) — Medical devices guidance documents — 30 September 2026